

Review Article

# The Role of IL-6 in Inflammatory Reaction during Coronavirus-19 Infection: A Review

Aesha S Ali<sup>1</sup>, Sadeq K Hachim<sup>2</sup>, Zainab M Saleh<sup>3</sup>

<sup>1</sup>Assistant Lecturer, Department of Microbiology, College of Medicine, Kirkuk University, Kirkuk, Iraq.

<sup>2</sup>Lecturer, PhD Medical Microbiology, Institute of Medical Technology, Baghdad, Middle Technical University, Iraq.

<sup>3</sup>Assistant Lecturer, Department of Pharmacy, Ashur University College, Iraq.

DOI: <https://doi.org/10.24321/0019.5138.202233>

## I N F O

### Corresponding Author:

Aesha S Ali, Department of Microbiology, College of Medicine, Kirkuk University, Kirkuk, Iraq.

### E-mail Id:

aysha.saber@uokirkuk.edu.iq

### Orcid Id:

<https://orcid.org/0000-0001-7240-4280>

### How to cite this article:

Ali AS, Hachim SK, Saleh ZM. The Role of IL-6 in Inflammatory Reaction during Coronavirus-19 Infection: A Review. Special Issue - COVID-19 & Other Communicable Disease. 2022;210-214.

Date of Submission: 2021-10-15

Date of Acceptance: 2021-11-23

## A B S T R A C T

Interleukin 6 (IL-6) is an interleukin that works as a pro-inflammatory cytokine and as an anti-inflammatory myokine. The production of IL-6 in humans is under genetic control. IL-6 is a pleiotropic cytokine created in response to tissue injury and infections. IL-6 is one of the basic cytokines after stimulated macrophages. Hence, control of systemic IL-6 levels in SARS-CoV-2 infected patients may be a consideration for COVID-19 disease. This review will focus on the role of IL-6 in diagnosis and follow up of infection in addition to being the target for treatment.

**Keywords:** COVID-19, IL-6, Inflammation, Cytokine

## Introduction

### Role of IL-6 in Immune Response

Interleukin 6 emitted from numerous cells including fibroblasts, keratinocytes, mesangials, vascular endothelial cells, mast cells, macrophages, dendritic cells just as T and B cells which are considered to be hotspots for IL-6 creation.<sup>1</sup> The enormous number of qualities arranged by IL-6 activity clarifies the pleiotropic idea of this interleukin. Thusly, the natural outcomes of IL-6 creation have been connected with both favourable to and mitigating effects,<sup>2</sup> underlining IL-6 basic job in the enactment and guideline of the human invulnerable reaction. Organic occasions influenced by the creation of IL-6 include control of the separation of monocytes to become macrophages by managing the outflow of macrophage province animating factor.<sup>3</sup> The IL-6 will impact humeral resistance by expanding B-cell IgG

creation by controlling the declaration of IL-21,<sup>4</sup> negative mandate of dendritic cell development by the enactment of the STAT3 flagging path,<sup>5</sup> and the enactment of the Th2 reaction by halting Th1 polarization. There are two distinct components that have been assigned to empower the hindrance of Th1 polarization by IL-6: (1) IL-6 inspires CD4 T cells to create IL-4 and by direct reaction to Th2, and (2) IL-6 influences the creation of IFN $\gamma$  by CD4 T cells, which think about fundamental interferon to advance Th1 extremity. A similar impact is delivered in Th1 cells, where hindrance of IFN $\gamma$  emission in these cells influences CD8 T cell activation.<sup>6</sup>

The IL-6 demonstration in blend with changing development factor beta to actuate separation of gullible CD4 into Th17 cells which play a significant part in insusceptible reaction at mucosal tissues.<sup>7</sup> IL-6 has a synergic impact with IL-7 and IL-15 to instigate the separation and cytolytic movement

of CD8 T cells.<sup>8</sup> The pyrogenic impact of IL-6 by association with lymphocyte deals with lymphoid organs during the febrile phase.<sup>9</sup>

### Role of IL-6 in Coronavirus Disease-19 Infection

COVID-19 is a type of contamination that is positive-sense with a single abandoned RNA illness that is widely spread among people and causes respiratory, gastrointestinal, hepatic, and neurologic problems.<sup>10</sup> SARS-CoV-2 is one of the beta coronaviruses of social events and is responsible for COVID-19 contamination. In addition, they share more than 70% of the same inherent progression as SARS-CoV-1. The percentage of patients who mention ARDS treatment is roughly 10% for those who are severely pampered. With a postponed approved thromboplastin time, the total white blood count, lymphocytes, and platelets are all lower than the average, similarly to muscle impetus level, stature in C-responsive protein. The number of lymphocytes decreases as contamination progresses. The cytokine storm, which includes IL1B, IL1RA, IL6, IL7, and IL8, is linked to the severity of contamination.<sup>11</sup> In individuals infected with SARS-CoV-1, there is an undeniable level of IL-6 during the acute stage, particularly with lung damage. Due to the SARS-CoV-1 attack on the respiratory tract, IL-6 can enhance the hyper-natural combustible response.<sup>12</sup> When differentiated from influenza virus, human epithelial cells have the option of delivering a higher proportion of IL-6 during SARS-CoV-1 pollutions.<sup>13</sup> The current situation is also present in COVID-19 patients infected with SARS-CoV-2. Several audits and meta-analysis studies explain how high IL-6 and C-responsive protein (CRP) levels are linked to mortality and actual illness, and more interestingly, with intermediate sickness.<sup>14,15</sup> IL-6, not IL-1 beta, is responsible for immunological dysregulation.<sup>16</sup> Because of dysregulation in monocytes and lymphocytes with CD4 lymphopenia, safe dysregulation occurs through the overproduction of a star provocative cytokine.<sup>17</sup> The relevant survey revealed that IL-6 plays a significant role in atypical lung injury (ALI), as evidenced by a mouse model in which IL-6 deficiency was shown to reduce the severity of ALI in the context of destructive breath. Both in humans and animals, SARS-CoV-1 has a limit of instigating the synthesis of artificial mixtures as oxidised phospholipid (OxPL). Through cost like receptor 4 (TLR4), this produced chemical will enable cytokine production and cause severe lung harm.<sup>18</sup> The preliminary goal was to explain how protection against influenza infections in mice models could be improved by focusing on TLR4 with friends or adversaries, no doubt with the express adversary of receptor antibodies.<sup>19</sup> We deduce from that the SARS-CoV-1 has the ability to cause serious lung injury and cytokine creation, similar to that of IL-6.<sup>19,20</sup>

### IL-6 as Indicative Instrument

Over the range of Corona disease 19, the gathering of

plasma protein Interleukin (IL)-6, IL-1 similarly as IL-10 were raised,<sup>21</sup> expressly, IL-6, which speedily convince the production of serious stage proteins considering illnesses and tissue wounds.<sup>22</sup> The change in IL-6 level mirrors the presence and earnestness of bothering, and they have for quite a while been used as a clinical guideline for finding the causes of diseases.<sup>21,23</sup>

In any event, the flammable IL-6 and ferritin haematological limitations (WBC, lymphocyte, neutrophil, platelet, and Hb) were obviously concurrent with the earnestness of COVID-19. Assessment of IL-6, Ferritin, and haematological records could be useful tests for ensuring, checking, and identifying COVID-19 patients.<sup>24</sup> According to Coomes EA et al., IL-6 levels are consistently elevated in COVID-19 individuals and are linked to dreadful clinical outcomes such as ICU admission, asthma, and destruction.<sup>25</sup> During COVID-19 disease, the fringe blood mononuclear cells show consistent TNF- $\alpha$  and IL-6 creation with LPS incitement ex-vivo and fundamentally raised IL-6 and C-responsive protein (CRP) focuses in vivo.<sup>26</sup> Impressively brought up in IL-6 levels (> 100 pg/mL), were painstakingly connected with observable serum SARS-CoV-2 viral load.<sup>27</sup> The new investigations showed that modified IL-6 remove esteems displayed unmistakable clinical importance as proposed by Gao Y et al. perceived the remove worth of 24.3 pg/ml of IL-6 connecting with D-Dimer for early acknowledgement of extreme cases in an associate of 43 cases.<sup>28</sup>

### The IL-6 Objective for Treatment

Interleukin 6 (IL-6) inhibitors have involved the middle of everyone's attention among the COVID-19 pandemic, and accepted the job of IL-6 in the cytokine storm period of COVID-19. Despite the fact that IL-6 inhibitors have been utilised for the therapy of insusceptible intervened sickness for quite a while, they have not been utilised in the intense escalated care setting. IL-6's potentially hazardous role in SARS-CoV-2 contamination has been demonstrated. As previously stated, significant levels of IL-6 have been linked to SARS-CoV-1 and SARS-CoV-2, and high serum levels of IL-6 have been linked to lung sores in SARS-CoV-2 patients in the severe and advanced phases.<sup>29</sup> Pointing the declaration of IL-6 with tocilizumab as a monoclonal neutraliser counter to the IL-6 receptor could be a legitimate option: this option is currently being used in some patients in Italy with major lung damages. Tocilizumab is now approved for the treatment of rheumatoid arthritis and other immune system diseases.<sup>30</sup> This decision should only be made if there are radiological and clinical signs that the lung sores are progressing. The most crucial decision in this outcome may be when to initiate the clinical organisation of anti-IL-6 drugs, because, as previously stated in murine models, IL-6 is necessary for the underlying phases of various contaminations to regulate sickness progression.<sup>31</sup>

Last updated on March 13, 2020, the suggested actions for providing tocilizumab were declared by the Italian Culture of Irresistible and Tropical Diseases (SIMIT, Societa Italiana di Malattie Infettive Tropical) as:

- During beginning stage with high popular heap of COVID-19
- In condition which requires obtrusive or non-invasive ventilation

The exemplary motioning of IL-6 assembles in the incitement of JAK/STAT pathway and in the MAPK flow.<sup>32</sup> The resulting stage subsequent to restricting of IL-6 to IL-6R and sgp130 is then to begin intracellular sign transduction. The sign transmission is accomplished by the Janus-kinase/ Signal transducer and activator of record (Jak/ STAT), for the most part, STAT1, STAT3 isoforms.<sup>33-35</sup> The conceivable approach to neutralising IL-6 activity is by restraining intracellular flagging pathway which leads to forestalling proinflammatory trans flagging pathway an has been accomplished for certain medications like Ruxolitinib.<sup>36</sup> JAK3 gives the impression to be less delicate to ruxolitinib.<sup>37</sup> It additionally has calming action which might be advantageous in its clinical use.<sup>38</sup> Ruxolitinib is too associated with the concealment of the unsafe sizes of macrophage activation haemophagocytic lymphohistiocytosis,<sup>39</sup> this clinical occasion is an under-known hyperinflammatory disorder described by fulminant and lethal hypercytokinemia with multi-organ failure.<sup>40</sup> The major fiery cytokines emitted by actuated macrophages as TNF and IL-6 will be lessened when presented to ruxolitinib.<sup>38</sup> This result upheld the thought that both ruxolitinib and tocilizumab have a similar component to hinder IL-6 and can consequently be utilised to treat the advance phase of COVID-19.

Baricitinib is one more medication that has been proposed for the treatment of SARS-CoV-2 infection.<sup>41</sup> This drug has a particular and incredible activity on JAK-STAT motioning by bringing down IL-6 I level as well as bringing down result rise in cytokine<sup>42</sup>. Clathrin-intervened endocytosis is likewise smothered by this medication which leads to hindered viral contamination to cells.<sup>43</sup> Baricitinib is a globally accepted medication during the beginning phase of contamination to forestall viral passage to the phones just as in late stage to smother provocative reaction.

## Conclusion

The past introduced information about The role of IL-6 during COVID-19 disease has been seen in the past. It has gained focus on account of its job in provocative reaction and complexity which happened during contamination and end to multiorgan disappointment because of cytokine storm, tool for finding and follow up the advancement of COVID-19 infection notwithstanding foresee result of disease.

**Conflict of Interest:** None

## References

1. Mauer J, Denson JL, Bruning JC. Versatile functions for IL-6 in metabolism and cancer. *Trends Immunol.* 2015 Feb;36:92-101. [PubMed] [Google Scholar]
2. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta.* 2011 May;1813:878-88. [PubMed] [Google Scholar]
3. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. *Nat Immunol.* 2000 Dec;1:510-4. [PubMed] [Google Scholar]
4. Yang R, Masters AR, Fortner KA, Champagne DP, Yanguas-Casás N, Silberberger DJ, Weaver CT, Haynes L, Rincon M. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells. *J Exp Med.* 2016 Oct;213:2281-91. [PubMed] [Google Scholar]
5. Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, Kamimura D, Ueda N, Iwakura Y, Ishihara K, Murakami M, Hirano T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. *J Immuno.* 2004 Sep;173:3844-54. [PubMed] [Google Scholar]
6. Green AM, Difazio R, Flynn JL. IFN-gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. *J Immunol.* 2013 Jan;190:270-7. [PubMed] [Google Scholar]
7. Guglani L, Khader SA. Th17 cytokines in mucosal immunity and inflammation. *Curr Opin HIV AIDS.* 2010 Mar;5(2):120-7. [PubMed] [Google Scholar]
8. Cox MA, Kahan SM, Zajac AJ. Anti-viral CD8 T cells and the cytokines that they love. *Virology.* 2013 Jan;435:157-69. [PubMed] [Google Scholar]
9. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nat Rev Immuno.* 2015 Jun;15:335-49. [PubMed] [Google Scholar]
10. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet.* 2020 Feb;395:473-5. [PubMed] [Google Scholar]
11. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther.* 2020;14:58-60. [PubMed] [Google Scholar]
12. Wang WK, Chen SY, Liu IJ, Kao CL, Chen HL, Chiang BL, Wang JT, Sheng WH, Hsueh PR, Yang CF, Yang PC, Chang SC; Severe Acute Respiratory Syndrome Research Group of the National Taiwan University College of Medicine/ NTU Hospital. Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression

- in patients with severe acute respiratory syndrome. *Clin Infect Dis*. 2004 Oct;39:1071-5. [PubMed] [Google Scholar]
13. Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, Takashima I, Tsutsumi H, Fujii N. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. *J Med Virol*. 2006 Dec;78:417-24. [PubMed] [Google Scholar]
  14. Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. *Virology*. 2009 Dec;395:210-22. [PubMed] [Google Scholar]
  15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020 Mar;395:1054-62. [PubMed] [Google Scholar]
  16. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, Ntaganou M, Kyriakopoulou M, Dimopoulos G, Koutsodimitropoulos I, Velissaris D, Koufargyris P, Karageorgos A, Katrini K, Lekakis V, Lupse M, Kotsaki A, Renieris G, Theodoulou D, Panou V, Koukaki E, Koulouris N, Gogos C, Koutsoukou A. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe*. 2020 Jun;27(6):992-1000.e3. [PubMed] [Google Scholar]
  17. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell*. 2008 Apr;133:235-49. [PubMed] [Google Scholar]
  18. Perrin-Cocon L, Aublin-Gex A, Sestito SE, Shirey KA, Patel MC, André P, Blanco JC, Vogel SN, Peri F, Lotteau V. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. *Sci Rep*. 2017 Jan;7:40791. [PubMed] [Google Scholar]
  19. Song J, Duncan MJ, Li G, Chan C, Grady R, Stapleton A, Abraham SN. A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. *PLoS Pathog*. 2007;3(4):e60. [PubMed] [Google Scholar]
  20. Gabay C. Interleukin-6 and chronic inflammation. *Arthritis Res Ther*. 2006;8 Suppl 2(Suppl 2):S3. [PubMed] [Google Scholar]
  21. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*. 2014 Sep;6(10):a016295. [PubMed] [Google Scholar]
  22. O'Neill L, McCormick J, Gao W, Veale DJ, McCarthy GM, Murphy CC, Fearon U, Molloy ES. Interleukin-6 does not upregulate pro-inflammatory cytokine expression in an ex vivo model of giant cell arteritis. *Rheumatol Adv Pract*. 2019 May;3(1):rkz011. [PubMed] [Google Scholar]
  23. Yazdanpanah P, Vafae F, Javdansirat S, Pouranfard J, Afrouz S. Diagnosis of Coronavirus disease by measuring serum concentrations of IL-6 and blood Ferritin. *Res Sq*. 2020;1:1-14. [Google Scholar]
  24. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. *Rev Med Virol*. 2020 Nov;30(6):1-9. [PubMed] [Google Scholar]
  25. Conrozier T, Lohse A, Balblanc JC, Dussert P, Royer PY, Bossert M, Bozgan AM, Gendrin V, Charpentier A, Toko L, Badie J, Mezher C, Roux MF, Kadiane-Oussou NJ, Contreras R, Kessler J, Mazurier I, Klopfenstein T, Zayet S. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. *Clin Exp Rheumatol*. 2020 Jul-Aug;38(4):742-7. [PubMed] [Google Scholar]
  26. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol*. 2020 Jul;92(7):791-6. [PubMed] [Google Scholar]
  27. Hsueh PR, Chen PJ, Hsiao CH, Yeh SH, Cheng WC, Wang JL, Chiang BL, Chang SC, Chang FY, Wong WW, Kao CL, Yang PC; SARS Research Group of National Taiwan University College of Medicine and National Taiwan University Hospital. Patient data, early SARS epidemic, Taiwan. *Emerg Infect Dis*. 2004;10:489-93. [PubMed] [Google Scholar]
  28. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. *Annu Rev Pharmacol Toxicol*. 2012;52:199-219. [Google Scholar]
  29. Pyle CJ, Uwadiae FI, Swieboda DP, Harker JA. Early IL-6 signaling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology. *PLoS Pathog*. 2017;13:e1006640. [PubMed] [Google Scholar]
  30. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. *Biochem J*. 2003 Aug;374:1-20. [PubMed] [Google Scholar]
  31. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signaling axis in cancer. *Nat Rev Clin Oncol*. 2018 Apr;15:234-48. [PubMed] [Google Scholar]
  32. Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. *Nat Immunol*. 2017 Mar;18:374-84. [PubMed] [Google Scholar]
  33. Zegeye MM, Lindkvist M, Fälker K, Kumawat AK, Paramel G, Grenegård M, Sirsjö A, Ljungberg LU. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response



- in human vascular endothelial cells. *Cell Commun Signal*. 2018 Sep;16(1):55. [PubMed] [Google Scholar]
34. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, aJAK1 and JAK2 inhibitor, in myelofibrosis. *N Engl J Med*. 2013 Sep;363:1117-27. [PubMed] [Google Scholar]
35. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupa M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. *Blood*. 2010 Apr;115:3109-17. [PubMed] [Google Scholar]
36. Bjorn ME, Hasselbalch HC. The impact of ruxolitinib treatment on inflammation mediated comorbidities in myelofibrosis and related neoplasms. *Clin Case Rep*. 2015 Jun;3:499-503. [PubMed] [Google Scholar]
37. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. *Blood*. 2016 Jul;128:60-71. [PubMed] [Google Scholar]
38. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet*. 2020 Mar;395:1033-4. [PubMed] [Google Scholar]
39. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis*. 2020 Apr;20(4):400-2. [PubMed] [Google Scholar]
40. Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, Marsala L, Niswonger J, Ritchey J, Alahmari B, Achilefu S, Tsunoda I, Schroeder MA, DiPersio JF. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. *Leukemia*. 2018 Nov;32:2483-94. [PubMed] [Google Scholar]
41. Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, Govero J, Nagamine CM, Diamond MS, De Jonghe S, Herdewijn P, Dye JM, Randall G, Einav S. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. *J Clin Invest*. 2017 Apr;127:1338-52. [PubMed] [Google Scholar]